Recce Pharmaceuticals Ltd
RECEF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $79 | $160 | $158 | $153 |
| - Cash | $10 | $4 | $2 | $12 |
| + Debt | $11 | $1 | $0 | $0 |
| Enterprise Value | $80 | $156 | $157 | $141 |
| Revenue | $8 | $7 | $4 | $3 |
| % Growth | 9.6% | 56.9% | 41.5% | – |
| Gross Profit | -$3 | -$0 | $4 | $3 |
| % Margin | -39.1% | -5.4% | 95% | 93.9% |
| EBITDA | -$20 | -$21 | -$17 | -$11 |
| % Margin | -270.8% | -311.7% | -389.2% | -350% |
| Net Income | -$21 | -$18 | -$13 | -$11 |
| % Margin | -285.4% | -257.8% | -299.6% | -356.1% |
| EPS Diluted | -0.09 | -0.1 | -0.074 | -0.063 |
| % Growth | 9.3% | -34% | -19% | – |
| Operating Cash Flow | -$20 | -$13 | -$13 | -$9 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$20 | -$13 | -$13 | -$9 |